Bayer continues to advance its comprehensive portfolio of radiology products through advances in the development pipeline and innovations in artificial intelligence (AI).

The company will present new data on gadoquatrane, the low-dose gadolinium-based macrocyclic contrast agent currently in Phase III development, at the Radiological Society of North America (RSNA) 2024 Annual Meeting, to be held December 1-5 in Chicago, USA.

At the meeting, Bayer also announced progress on a collaboration with global medical technology company Subtle Medical.

"The common goal is to harness the power of AI in medical imaging: The companies have agreed to advance the development of the SubtleGAD experimental deep learning algorithm, with the aim of enabling experimental dose reduction of specific gadolinium-based contrast agents for patients undergoing contrast-enhanced MRI, while maintaining diagnostic efficacy' says the group.

Copyright (c) 2024 CercleFinance.com. All rights reserved.